Pay in 4 interest-free payments of $6.71 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Frequently Asked Questions At what age does this guide say tirzepatide is approved, and why not younger
Have more questions before you schedule a new patient visit
Constipation and digestive discomfort Constipation on tirzepatide is the second most common gastrointestinal complaint after nausea
Clinical trials show approximately 1015% weight reduction over 68 weeks in adults with obesity, comparable to lower-dose injectable semaglutide due to different pharmacokinetics
For patients with established atherosclerotic cardiovascular disease, injectable agents with proven outcome data may still be preferred
Tirzepatide (Mounjaro, Zepbound) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist approved by the FDA for type 2 diabetes management (Mounjaro) and chronic weight management (Zepbound)
